Castle Biosciences

The cancer molecular diagnostics firm said it will use the proceeds from the offering to support its R&D activities and for general corporate purposes.

The skin cancer diagnostics company said it delivered 42 percent more DecisionDx-Melanoma test results in Q1 2020 than in the previous year's first quarter.

The skin cancer diagnostics company said it delivered 37 percent more DecisionDx-Melanoma test results in Q4 2019 than in the previous year's fourth quarter.

The GenomeWeb Index fell 2 percent, outperforming the Nasdaq Biotechnology Index but doing worse than the Dow Jones and the Nasdaq.

The company said it delivered 4,480 DecisionDx-Melanoma test reports in Q4 2019 compared to 3,270 reports in Q4 2018.

The GenomeWeb Index vastly outperformed the Dow Jones and the Nasdaq Biotechnology Index this month, while slightly underperforming the Nasdaq.

The skin cancer test developer reported total revenues of $14.8 million compared to $3.7 in Q3 2018, beating the Wall Street expectation of $9.5 million.

The GenomeWeb index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.